Osteoporosis - An update

Acta Obstetricia et Gynecologica Scandinavica

Volumn 76, Issue 3, 1997, Pages 189-199

  Samsioe, Göran ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone fracture; Bone fragility; Bone loss; Bone mineral density; Osteoporosis

Indexed keywords

ACCURACY; ASIA; BONE MASS; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; EUROPE; FEMALE; FRACTURE; HEALTH CARE COST; HEREDITY; HUMAN; LIFESTYLE; MEASUREMENT; MENOPAUSE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0030956651     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0412.1997.tb07844.x     Document Type: Review

References (97)

1. World Congress on Osteoporosis. Consensus Committee, Amsterdam 1996 (in press).
2. WHO Study Group. Assessment of fracture risk and its application to screening to postmenopausal osteoporosis. WHO Technical Report Series 843, 1994.
3. Lindsay R. The burden of osteoporosis costs. Am J Med 1995; 98: 9-11.
4. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: A world-wide projection. Osteo Int 1992; 2: 285-9.
5. Lauritzen JB, Schwarz P, Lund B, McNair P, Transbol I. Changing incidence and residual lifetime risk of common osteoporosis related fractures. Hvidovre Osteoporosis Study Osteoporosis Int 1993; 3: 127-32.
6. Naessén T, Parker R, Persson I, Zack M, Amadi H-O. Time trends in incidence rates of first hip fracture in the Uppsala health care region, Sweden, 1965-1983. Am J Epidemiol 1987; 130: 279-87.
7. Melton LJ, O'Fallon WM, Riggs BL. Secular trends in the incidence of hip fractures. Calcif Tissue Int 1987; 41: 57-64.
8. Johnell O, Gullberg B, Allander A, Kanis JA. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporosis Int 1992; 2: 298-302.
9. Riggs BL, Melton LJ. Age related incidence of osteoporotic fractures. New Engl J Med 1986; 314: 1676-86.
10. Holbrook TL, Grazier K, Kelsey JL, Stauffer RN. The frequency and occurrence, impact and cost of selected muscoloskeletal conditions in the United States. American Academy of Orthopedic Surgeons, Chicago 1984.
11. Schütte HE. Social and economic impact of osteoporosis. A review of the literature. Eur J Radiol 1995; 20: 165-9.
12. Sernbo J, Johnell O. Consequences of a hip fracture: a prospective study of 1 year. Osteoporosis Int 1993; 3: 148-53.
13. Lindsay R. The menopause and osteoporosis. Obstet Gynecol 87: suppl 1996; 2: 16S-19S.
14. Bengner U. Age related fractures. Medical dissertation, Lund 1987.
15. Johnell O. Effect of oestrogen treatment on incidence of fragility fractures. Acta Orthoped Scand, 1995.
16. Flicker L, Hopper JL, Rodgers L, Kaymakei B, Green RM, Wark JD. Bone density determinants in elderly women: a twin study. J Bone Miner Res 1995; 10: 1607-13.
17. Guéguen R, Jouanny P, Guillemin F, Kuntx C, Pourel J. Segregation analysis and variance components analysis of bone mineral density in healthy families. J Bone Miner Res 1995; 10: 1027-2022.
18. Howard G, Nguyen T, Morrison N, Watanabe T et al. Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metab 1995; 80: 2800-5.
19. Barger-Luz MJ, Heaney-RP, Hayes J, DeLuca HF, Johnson ML, Gong G. Vitamin D receptor gene polymorphism, bone mass, body size, and vitamin D receptor density. Calcif Tissue Int 1995; 57: 161-2.
20. Bedalov A, Salvatori R, Dodig M, Kronenberg MS et al. Regulation of COLT A1 expression in type I collagen producing tissues: identification of a 49 base pair region which is required for transgene expression in bone of transgenic mice. J Bone Miner Res 1995; 10: 1443-51.
21. Sano M, Inoue S, Hosoi T, Ouchi Y et al. Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun 1995; 217: 378-83.
22. Högåsen AKM, Nordsletten L, Aasen AO, Falch JA. There is no difference in spontaneous and 17-β-estradiol-induced interleukin-1-β release by peripheral blood mononuclear cells from non osteoporotic women with different rates of early postmenopausal bone loss. J Clin Endocrinol Metab 1995; 80: 2480-4.
23. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 1995; 136: 3054-61.
24. Gunnes M, Lehmann EH, Cecor AS. Dietary calcium saturated fut, fiber and vitamin C as predictors of forearm cotical arid trabecular bone mineral density in healthy children and adolescents. Acta Paediatr 1995; 84: 388-92.
25. Prior JC, Vigna YM, Schlechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med 1990; 323: 1221-7.
26. Hergenroeder AC. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995; 126: 683-9.
27. Garnero P, Sornay-Rendu E, Delmas PD, Hôp E. Decreased bone turnover in oral contraceptive users. Bone 1995; 16: 499-503.
28. Bonjour JP et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73: 555-63.
29. Gilsanz V et al. Peak trabecular vertebral density: a comparison of adolescent girls and adult females. Calcif Tissue Int 1988; 43: 260-2.
30. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? Br Med J 1989; 298: 924-8.
31. Teitelbaum SL, Cao X, Mimura H, Chiba M, Ross PF. Cellular and molecular mechanisms of bone resorption. Miner Elecytrolyte Metab 1995; 21: 193-6.
32. Buckwalter JA, Glimcher MJ, Cooper RR, Recker R. Bone biology. Part I + Part II. J Bone Joint Surg 1995; 77A: 1256-89.
33. Horne WC. Toward a more complete molecular description of the osteoclast. Bone 1995; 17: 107-9.
34. Mundy GR. Local control of bone formation by osteoblasts. Clin Orthop 1995; 313: 19-26.
35. Menkès C-J. Metabolic bone disease. Curr Opin Rheumatol 1995; 7: 235-6.
36. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 1994; 55: 82-6.
37. Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995; 17: 680-5.
38. Juppner H. Functional properties of the PTH/PTHrP receptor. Bone 1995; 17: 39-42.
39. Cate JC, Papadea C. Parathyroid hormone. Part I+II. Measurement and clinical use. Lab Med 1995; 26: 599-602.
40. Arner EC, Tortorella MD. Signal transduction through chondrocyte integrin receptors induces matrix metalloproteinase synthesis and synergizes with interleukin-1. Arthritis Rheum 1995; 38: 1304-14.
41. Manolagas SC. Role of cykotines in bone resorption. Bone 1995; 17: 63-7S.
42. Bismar H, Diel I, Ziegler R, Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995; 80: 3351-5.
43. Mundy GR, Boyce B, Hughes D, Wright K et al. The effects of cytokines and growth factors on osteoblastic cells. Bone 1995; 17: 71-5S.
44. Levitt Katz LE, Rosenfeld RG, Cohen SP. Clinical significance of insulin-like growth factor binding proteins (IGFBPs). Endocrinologist 1995; 5: 36-43.
45. Rosen CJ, Donahue LR. Insulinlike growth factors: potential therapeutic options for osteoporosis. Trends Endocrinol Metab 1995; 6: 235-41.
46. Kanatani M, Sugimoto T, Kaji H, Kano J, Chihara K. Effects of 22-oxacalcitriol on bone metabolism in vitro: comparison with calcitriol. Effects of 22-oxacalcitriol on osteoclast-like cell formation and bone-resorbing activity. Eur J Endocrinol 1995; 133: 618-25.
47. Ooms ME, Roos JC, Bezemer PH, van der Vijgh WJF et al. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995; 80: 1052-8.
48. Labram EK, Wilkin TJ. Growth hormone deficiency in adults and its response to growth hormone replacement. Q J Med 1995; 88: 391-9.
49. Delmas P-D. The new definition of osteoporosis: implications for diagnosis and treatment. In: Menopause. European Consensus Development. MH Birkhäuser, H Rozenbaum (eds). ISBN 2 86911-422 2. Montreux, Switzerland, 1996.
50. Hassager C, Christiansen C. Measurements of bone mineral density. Calcif Tissue Int 1995; 57: 1-5.
51. Cheung CK, Panesar NS, Haines C, Masarei J, Swaminathan R. Immunoassay of a tartrate-resistant acid phosphatasc in serum. Clin Chem 1995; 41: 679-86.
52. Åkesson K, Vergnaud Ph, Delmas PD, Obrant KJ. Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone 1995; 16: 427-30.
53. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients. J Clin Endocrinol Metab 1995; 80: 2447-50.
54. Kamel S, Brazier M, Neri V, Picard C et al. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. J Bone Miner Res 1995; 10: 1385-92.
55. Arbault P, Grimaux M, Pradet V, Preaudat C et al. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone 1995; 16: 461-7.
56. Palmieri GMA. Calcium why and how much? Miner Electrolyte Metab 1995; 21: 236-41.
57. Steiniche T, Hasling C, Charles P, Eriksen EF et al. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989; 10: 313-20.
58. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; ii: 1151-4.
59. Lindsay R, Hart D M, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759-63.
60. Lindsay R, Hart DM, MacLean A, Clark AC et al. Bone response to termination of oestrogen treatment. Lancet 1978; i: 1325-7.
61. Felson DT, Zhang Y, Hannan MT, Kiel DP et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-6.
62. Tohme J, Cosmn F, Lindsay R. Osteoporosis. In: Principles and Practices of Endocrinology and Metabolism. KL Becker (ed). 2nd ed. JB Lippincott, pp. 567-85, 1995.
63. Reginster JY, Deroisy R, Lecart MP, Sarlet N et al. A doubleblind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452-8.
64. Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civetelli R. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50: 381-3.
65. Azria M. 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995; 57: 405-8.
66. Chesnut CH III, McClung Mr, Ensrud KE, Bell NH et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52.
67. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99: 36-42.
68. Goebel JA, Birge SJ, Price SC, Hanson JM et al. Estrogen replacement therapy and postural stability in the elderly. Am J Otol 1995; 16: 470-4.
69. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99: 235-42.
70. Filipponi P, Pedetti M, Fedeli L, Cini L et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995; 10: 697-703.
71. Francis RM. Oral bisphosphonates in the treatment of osteoporosis - a review. Curr Ther Res 1995; 56: 831-51.
72. Chapuy MC, Arlot ME, Duboeuf F, Brun J et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.
73. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE et al. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 1995; 61: 1140-5.
74. Byrne PM, Freaney R, McKenna MJ. Vitamin D supplementation in the elderly: review of safety and effectiveness of different regimes. Calcif Tissue Int 1995; 56: 518-20.
75. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB et al Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-63.
76. Reid IR, Arnes RW, Evans MC, Gamble GD, Sharpe SJ. Longterm effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98: 331-5.
77. Kohrt WM, Birge SJ Jr. Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist and total body in late postmenopausal women. Osteoporosis Int 1995; 5: 150-5.
78. Haines CJ, Chung TKH, Leung PC, Hsu SYC, Leung DHY. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy. Bone 1995; 16: 529-31.
79. Takada J, Baylink DJ, Lau K-HW. Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells. J Bone Miner Res 1995; 10: 1512-22.
80. Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Effect of the fluoride-calcium regimen on the vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982; 306: 445-50.
81. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995; 123: 401-8.
82. Kauffman RK, Bryant HU. Selective estrogen receptor modulators. DN&P 1995; 8: 531-9.
83. Rymer J, Chapman M, Fogelman I. The effect of tibolone on postmenopausal bone loss. Menopause Digest 1995; 4: 16-7.
84. Poór G, Atkinson EJ, Lewallen DG, O'Fallon WM, Melton LJ III. Age-related hip fractures in men: clinical spectrum and shortterm outcomes. Osteoporosis Int 1995; 5: 419-26.
85. Luisetto G, Mastrogiacomi I, Bonanni G, Pozzan G et al. Bone mass and mineral metabolism in Klinefelter's syndrome. Osteoporosis Int 1995; 5: 455-61.
86. Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol 1995; 14 (suppl. 3): 32-9.
87. Marel GM. Osteoporosis in men. Curr Ther 1995; 36: 21-7.
88. Orwoll ES, Klein RF. Osteoporosis in men. Endocrine Reviews 1995; 16: 87-116.
89. Goldbloom R, Battista RN. The periodic health examination: 1. Introduction. Can Med Assoc J 1988; 138: 617-26.
90. Swedish Council on Technology Assessment in Health Care (SBU). SBU Bone Density Project. Overview & Summary of Previous Reports. Stockholm, Sweden, SBU, April 1994.
91. Office of Technology Assessment. Congress of the United States. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Vol. 1: Cost-Effectiveness Analysis. Washington, DC, August 1995.
92. Kanis JA. The future of HRT and osteoporosis: an epidemiologic perspective. Menopause. European Consensus Development. Montreux, Switzerland. 1996; pp. 269-76.
93. Grady D, Rubin SM, Petitti DB, Fox CS et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
94. Ettinger B, Grady D. Maximizing the benefit of oestrogen therapy for prevention of osteoporosis. J North Am Menopause Soc 1994; 1: 19-24.
95. Agence Nationale pour le Développement de l' Evaluation Médicale, Evaluation of Bone Mineral Density Measurement. Paris, France: ANDEM, October 1991.
96. 'Germany Doubts Value of Osteoporosis Screening'. Clinica October 1994; 7, 626.
97. University of Leeds, School of Public Health, and University of York, Royal College of Physicians, Screening of Osteoporosis to Prevent Fractures, Effective Health Care January 1992; 1: 1-10.